Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 129 results for "Byetta"

Human medicines European public assessment report (EPAR): By...

This is a summary of the European public assessment report (EPAR) for Byetta. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and ... European Medicines Agency, 1 week ago

2 images for "Byetta"

HealthCentral.com, 4 months ago
NewsGrio, 6 months ago
Share Market Updates

Teva Settles Patent Litigation with AstraZeneca Allowing Teva to Commercialize Its Generic Version of Byetta Exenatide Injection in the United States

By a News Reporter-Staff News Editor at Pharma Business Week Teva Pharmaceuticals USA, Inc., (NYSE and TASE:TEVA) announced that they have settled the patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Amylin Pharmaceuticals, ...
 Pharmacy Choice1 month ago Teva settles generic Byetta patent litigation with AstraZeneca  PharmaBiz1 month ago Teva and AstraZeneca settle Byetta patent fight  Seeking Alpha2 months ago TEVA PHARMACEUTICAL : Settles Patent Litigation with AstraZeneca Allowing to Commercialize Its Generic Version of Byetta┬« (Exenatide Injection) in the United States  4 Traders2 months ago
[x]  

AstraZeneca, Teva settle Byetta patent suit; generics on their way

Immediately following AstraZeneca's big FluMist setback Thursday, the British pharma has entered into an agreement with Teva that will likely lead to sales losses for another product, Byetta. AstraZeneca and Teva settled patent disputes over the ...
 CPhI.cn1 month ago
Pharmacy News

Weekly exenatide listed for type 2 diabetes

A once-weekly subcutaneous injection ofexenatide is being funded on the PBS as part of a $70 million round of new listings. The glucagon-like peptide-1 (GLP-1) analogue has been available on the PBS as a twice-daily subcutaneous injection ...
 Pharmacy News1 week ago Once-weekly diabetes drug gets funding  6minutes.net.au1 week ago
Medical News Today

Health Australia to subsidise under PBS beginning Sept 1 Exanatide, new drug for type 2 diabetics

Relief is on the way for type 2 diabetics in Australia whose blood sugar test strip subsidy would be removed beginning 2017. A new medicine would not only be subsidised under the Pharmaceutical Benefits Scheme (PBS), but it would also mean less ...
 International Business Times Australia1 week ago Sanofi Should Be Thinking Longer Duration In GLP-1s  Seeking Alpha3 weeks ago Monthly News Roundup - July 2016  Drugs.com3 weeks ago FDA OKs New Injectable Type 2 Diabetes Medication  US News & World Report3 weeks ago
[x]  

Achievements of Global TOP10 Pharmaceutical Enterprises in the First Half of 2016 - Part 2

Achievements of the pharmaceutical giants in the first half of this year have come out, as the global top 10 pharmaceutical enterprises released their 2016Q2 reports in succession. Revenues of top 10 pharmaceutical enterprises in 2016H1- Part 2 ...
 CPhI.cn1 week ago Pharmaceuticals Newsletter - June 20 to 24, 2016  India Infoline2 months ago

AstraZeneca Solid And Safe, With Upside From Biologic Pipeline

AstraZeneca (NYSE: AZN ) released its Q2 and first half 2016 results with an upbeat analysis. Q2 results positive and well received AZN is trading at close to a year high, up 8.7% to $34.29 today on good Q2 results. Q2 earnings of $0.83/share ...
 Seeking Alpha3 weeks ago
CPhI.cn

Major players in Type II diabetes shifting focus to pricing to maintain market share

According to a report by GlobalData, human insulins and many insulin analogs are currently off patent or will soon lose their patents The highly mature Type II diabetes (T2D) market, which is forecast to be valued at $58.7 billion by 2025, will ...
 Express Pharma1 month ago Major Players in Type 2 Diabetes Shift Focus to Pricing  CPhI.cn1 month ago GLOBALDATA : Companies prioritise competitive pricing in type 2 diabetes, says GlobalData  4 Traders1 month ago Type 2 Diabetes Market: Competitive Pricing to Offset Patent Expiries  PharmaceuticalProcessing1 month ago
[x]  
Seeking Alpha

Buy vTv Therapeutics For Its Novel Alzheimer's And Anti-Diabetic Drug Candidates.

vTv Therapeutics (NASDAQ: VTVT ) is an emerging biopharmaceutical company that is using a proprietary drug discovery engine called TTP transitional technology to develop novel drugs for common diseases like Alzheimer's disease and type 2 diabetes.
 Seeking Alpha1 month ago

The global type 2 diabetes market is projected to reach $58.7bn by 2025

The global type 2 diabetes (T2D) market is projected to reach $58.7bn by 2025, driven by competitive pricing adopted by pharmaceutical companies, according to a GlobalData report. Titled PharmaPoint: Type 2 Diabetes Global Drug Forecast and ...
 CPhI.cn1 month ago Report: Pricing to take precedence as pharmaceutical companies strive to remain profitable within mature type 2 diabetes market  Pharmaceutical Technology1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less